Jvion Achieves Remarkable Infection Control Predictive Outcomes
Atlanta, GA (PRWEB) September 26, 2014 -- According to a recent study released by The Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team, 452 out of 11,282 sample patients acquired a healthcare-associated infection (also know as hospital acquired infection or HAI) across 183 hospitals in 2011. Pneumonia topped the list, followed by surgical-site infections, gastrointestinal infections, urinary tract infections, and primary blood stream infections. Estimates based on this study put the number of patients with HAIs in U.S. hospitals during 2011 at more than half a million.
The problem of HAIs is the target of hospital infection control programs. However, according to a study in the American Journal of Infection Control, many hospitals show disparate/uneven results in the effectiveness of hospital infection prevention efforts across HAIs. This is in large part due to understaffed programs, inconsistent policies, underutilized technologies, and a lack of clinician adherence to infection prevention policies.
Recognizing this gap, Jvion applied their RevEgis clinical predictive solution to the challenge of infection control programs. Shantanu Nigam, Jvion’s CEO, commented that, “if other industries can apply such technologies, why is healthcare not open to adopting the predictive means we now have? Using advanced mathematical concepts and artificial intelligence capabilities, RevEgis provides predictions across a patient population to target infection prevention resources. Individual patient-level risk stratifications are aggregated and fed directly into the infection control program workflow to drive improved health outcomes using the prevention resources that are already in place. And because of the initial five year investment in research and development that went into the solution while in a stealth state, we can do this in weeks, not months.”
The firm is delivering accuracy results that are remarkable and helping identify patient-level conditions correctly 9 times out of 10 in most situations. And according to a company spokesperson, the RevEgis solution is already pre-configured with machine intelligence to tackle the biggest infection problems “out-of-the-box.”
Shantanu went on to say that, “the question to ask doctors is this ‘what if you knew that 8 or 9 out of 10 patients were going to get a certain infection or never event, wouldn’t you do something differently?’” Shantanu continued, “this simple shift in mindset can change how medicine is delivered, reduce billions of dollars in waste by leveraging advanced algorithms and technologies, and help a hospital improve the quality of the care delivered while saving millions in unreimbursed cost.”
To learn more about Jvion and their full suite of Big Data predictive analytic solutions for healthcare, please visit http://www.jvion.com.
About Jvion
Jvion is a healthcare technology company that develops software designed to predict and prevent patient-level disease and financial losses leading to increased waste. The company offers a suite of big-data enabled solutions that combine clinical intelligence with deep machine learning to help providers protect their revenues while improving patient health outcomes. Their objective is simple—stop the waste of resources and lives by predicting and stopping losses before they ever happen.
###
Allison Alavi, Jvion, http://www.jvion.com, +1 404 483 3713, [email protected]
Share this article